LYFCX Performance — AlphaCentric Life Sciences and Healthcare Fund, Class C
Data updated: 2026-08-27
LYFCX returned +16.76% year to date and +53.22% over one year to Jun 2026. Annualised returns are +12.32% over 3 years and +6.79% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $142, against $138 for the category, and to $153 over one year, against $137. Volatility over the past three years was 19.83% a year. In the 12 months to Jun 2026 the fund lost a net $3.5M, and assets reached $46.65M.
LYFCX Growth of $100
What $100 invested in AlphaCentric Life Sciences and Healthcare Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | LYFCX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $153 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $142 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $139 | $121 |
| Since data start (Oct 2019 – Jun 2026) | $228 | $193 |
LYFCX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +16.76% |
| 1 year | +53.22% |
| 3 years (annualised) | +12.32% |
| 5 years (annualised) | +6.79% |
LYFCX Annual Returns
Calendar-year total returns of AlphaCentric Life Sciences and Healthcare Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +16.76% |
| 2025 | +26.96% |
| 2024 | −1.22% |
| 2023 | +6.14% |
| 2022 | −1.82% |
| 2021 | −4.32% |
| 2020 | +54.33% |
| 2019 (Oct–Dec) | +1.30% |
LYFCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.9% | +2.2% | −3.6% | +0.2% | +4.5% | +12.2% | — | — | — | — | — | — |
| 2025 | +5.6% | 0.0% | −2.7% | −3.6% | −4.2% | +1.9% | −1.6% | +6.6% | +5.5% | +10.9% | +8.4% | −1.3% |
| 2024 | −4.1% | +3.2% | +0.1% | −8.5% | +2.8% | +1.0% | +9.8% | +6.1% | −3.0% | +0.1% | −0.3% | −6.8% |
| 2023 | +17.8% | −4.2% | −5.5% | +2.8% | −1.5% | +1.4% | +6.1% | −4.4% | −7.6% | −10.8% | +4.2% | +11.1% |
| 2022 | −3.2% | −0.2% | +6.1% | −13.8% | −4.7% | +7.1% | +6.3% | −0.6% | −7.8% | +4.8% | +5.3% | +1.3% |
| 2021 | +2.9% | +3.2% | −4.3% | +1.6% | −1.3% | +3.1% | −9.8% | +9.0% | −2.5% | −1.9% | −7.7% | +4.8% |
| 2020 | −0.2% | −2.8% | −2.9% | +9.2% | +7.9% | +0.2% | −3.2% | +4.8% | +7.4% | +3.1% | +16.5% | +6.0% |
| 2019 | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | +1.3% |
LYFCX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 19.83%
- 3-year Sharpe ratio: 0.39 (vs 4.5% risk-free rate)
- Best month: +12.21% (Jun 2026)
- Worst month: −10.77% (Oct 2023)
LYFCX Fund Flows
Monthly money in and out of AlphaCentric Life Sciences and Healthcare Fund, from SEC Form N-PORT.
- 12-month net flow: −$3.5M
- 12-month gross sales (incl. reinvestments): $9.7M
- Sales ÷ redemptions: 0.73×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $1.2M | $920K | $256K |
| May 2026 | $439K | $319K | $120K |
| Apr 2026 | $196K | $275K | −$78K |
| Mar 2026 | $606K | $548K | $57K |
| Feb 2026 | $274K | $393K | −$118K |
| Jan 2026 | $3.1M | $580K | $2.5M |
| Dec 2025 | $1.0M | $583K | $443K |
| Nov 2025 | $1.1M | $984K | $134K |
| Oct 2025 | $412K | $4.2M | −$3.8M |
| Sep 2025 | $474K | $901K | −$427K |
| Aug 2025 | $455K | $1.3M | −$802K |
| Jul 2025 | $500K | $2.3M | −$1.8M |
LYFCX Assets Under Management
Net assets of AlphaCentric Life Sciences and Healthcare Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $46.65M |
| 2026-03-31 | $39.32M |
| 2025-12-31 | $37.02M |
| 2025-09-30 | $34.86M |
| 2025-06-30 | $34.42M |
| 2025-03-31 | $44.20M |
| 2024-12-31 | $52.67M |
| 2024-09-30 | $82.91M |
| 2024-06-30 | $82.81M |
| 2024-03-31 | $103.23M |
| 2023-12-31 | $104.23M |
| 2023-09-30 | $103.37M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.